Patients With Advanced Non-small Cell Lung Cancer Harboring MET Alterations: A Descriptive Cohort Study.

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Mesenchymal-epithelial transition factor (MET) alterations are rare but significant oncogenic drivers in non-small cell lung cancer (NSCLC).
• Understanding the clinical characteristics, treatment patterns, and outcomes of patients with MET exon 14 (METex14) skipping and MET amplification (METamp) is crucial for personalized medicine.

Purpose of the Study:

• To characterize patients with advanced NSCLC and METex14 skipping and/or MET amplification in a real-world clinical setting in the United States.
• To describe patient demographics, treatment strategies, and clinical outcomes associated with these rare genetic alterations.

Main Methods:

• Retrospective analysis of electronic medical record data from the ConcertAI Oncology Dataset (2004-2022).
• Identification and comparison of two patient cohorts: METex14 skipping (with or without METamp) and METamp without METex14 skipping.
• Subgroup analysis of patients with METamp and EGFR mutations treated with EGFR-tyrosine kinase inhibitors (TKIs).

Main Results:

• 93 patients with METex14 skipping and 164 with METamp were identified in advanced NSCLC.
• Decreased use of first-line chemotherapy over time, with increased use of immune checkpoint inhibitors (ICIs) and MET inhibitors.
• Improved outcomes for METex14 skipping NSCLC patients treated with targeted therapies or ICIs compared to chemotherapy; poor outcomes noted in EGFR-TKI-treated METamp subgroup.

Conclusions:

• Patients with METex14 skipping and/or METamp NSCLC have an unmet medical need requiring targeted and personalized treatment approaches.
• The availability of novel targeted therapies and ongoing research hold promise for significantly improving treatment outcomes in NSCLC patients with these rare drivers.